scispace - formally typeset
D

Diego Albani

Researcher at Mario Negri Institute for Pharmacological Research

Publications -  190
Citations -  13004

Diego Albani is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Bipolar disorder & Population. The author has an hindex of 35, co-authored 178 publications receiving 10355 citations. Previous affiliations of Diego Albani include National Research Council.

Papers
More filters
Journal ArticleDOI

Multidisciplinary Perspectives for Alzheimer's and Parkinson's Diseases: Hydrogels for Protein Delivery and Cell-Based Drug Delivery as Therapeutic Strategies:

TL;DR: Only interdisciplinary research that fully integrates biology, biochemistry, medicine and materials science can provide a springboard for the development of suitable therapeutic tools, not only for the treatment of Alzheimer's and Parkinson's diseases but also, prospectively, for a wide range of severe neurodegenerative disorders.
Journal ArticleDOI

An Organ-On-A-Chip Engineered Platform to Study the Microbiota-Gut-Brain Axis in Neurodegeneration.

TL;DR: An innovative groundbreaking bioengineering approach is discussed that could make a difference in this intriguing scenario of neurodegenerative disorders such as Alzheimer's or Parkinson's disease.
Journal ArticleDOI

Physical activity, socialization and reading in the elderly over the age of seventy: what is the relation with cognitive decline? Evidence from "The Treviso Longeva (TRELONG) study".

TL;DR: The correlations between physical activity, socialization, reading and improved cognitive performance remained significant after adjusting for confounding factors, such as comorbidity and hearing function.
Journal ArticleDOI

Nanocomposites for Neurodegenerative Diseases: Hydrogel-Nanoparticle Combinations for a Challenging Drug Delivery:

TL;DR: Material science can provide a powerful tool to design hydrogels and nanoparticles as basic components of more complex nanocomposites that might ameliorate drug or cell delivery in AD/PD, which might increase brain targeting of neuroprotective molecules or proteins.